Please assess the completion status of the following clinical trial:

Trial Title: Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA~1. \>18 years of age~2. Has undergone allo HSCT to treat a B-cell derived hematologic malignancy: accepted alloHSCT regimens include: myeloablative or reduced intensity conditioning from any donor (matched, partially mismatched or cord) and any source (peripheral blood, bone marrow, or cord).~3. T bili ≤ 1.5 mg/dL except for patients with Gilbert's syndrome or hemolysis~4. AST, ALT and alk phos all \< 2.5X ULN~5. Karnofsky performance score ≥ 40~6. ECOG ≤3~7. For women of childbearing potential, a negative serum or urine pregnancy test with sensitivity less than 50 mIU/m within 72 hours before the start of study medication.~8. Use of two forms of contraception with less than a 5% failure rate or abstinence by all transplanted patients for a minimum of 1 month after the last dose of Idelalisib. For the first 60 days post-transplant, transplant recipients should be encouraged to use non-hormonal contraceptives due to the potential adverse effect of hormones on bone marrow engraftment.~9. Ability to receive oral medication.~10. Ability to understand and provide informed consent.~EXCLUSION CRITERIA~1. ECOG \>3 (Karnofsky \<40%)~2. ALT, AST \>2.5 ULN or total bilirubin \>1.5 ULN (not attributable to Gilbert's)~3. Women who are pregnant or breastfeeding.~4. Exclude if patient has cirrhosis or is currently being actively treated for hepatitis C.~5. History of positive HIV-1 or HIV-2 serologies or nucleic acid test.~6. Active hepatitis B infection as documented by positive Hepatitis B PCR assay~7. Use of investigational drug, other than the study medications specified by the protocol, within 30 days of transplantation.~8. Receipt of a live vaccine within 30 days of receipt of study therapy.~9. ≥ Grade II aGVHD~10. The presence of any medical condition that the Investigator deems incompatible with participation in the trial~11. Subjects who are required to use a medication classified as a strong CYP3A inducer of inhibitor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Idelalisib 100mg (Type: EXPERIMENTAL): Idelalisib is an orally-administered, selective inhibitor of Phosphoinositide 3 kinase (PI3K)-delta which has been shown to be extremely effective in inducing partial to complete responses in many B-cell derived malignancies.~intervention: 100mg Idelalisib twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant
- Placebo oral tablet (Type: PLACEBO_COMPARATOR): Placebo to be taken twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).